Officiis Properties : Signature of a provisional sales

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
35
Officiis Properties : Signature of a provisional sales agreement for the Newtime building

Press Release Paris, February 6 th , 2019

Signature of a Provisional Sales Agreement for the Newtime Building

Officiis Properties, a listed company on Euronext Paris, announces that, following a tender process, its subsidiary Officiis Properties Ouest 1 has signed on this day a provisional sales agreement of the Newtime building (located on the Ile de la Jatte in Neuilly-sur-Seine) for a net selling price of €156.8 million, accompanied by a rental guarantee granted by Officiis Properties Ouest 1 of €2.6 million. The completion of this sale should take place during the second quarter of 2019.

After taking into account the deduction of advisory fees and expenses and the freezing of the rental guarantee on an escrow account, the Company estimates that it should collect a net amount of approximately €152.3 million at the time of sale.

It is recalled that during the 4 th quarter of 2018, the group:

  • has disposed of the Think and Imagine buildings 1 ,
  • has reimbursed the mortgage loan associated with the Magellan building 1 ,
  • has refinanced the Newtime building through a new mortgage loan 1 , 
  • has completed a partial reimbursement of its subordinated non-bank loan 1 .

As a result of these operations, as of the time of this press release,

  1. the group possesses two buildings:
    • the Magellan building, which JLL estimates is worth €32 million. This building, which was vacated by Faurecia at the end of November 2018, will be the subject of renovation works during 2019 (estimated budget of €12 million including taxes),
    • the Newtime building, whose disposal for an amount net of fees and expenses of €152.3 million is the object of this press release
  2. the group has a net cash position of €18 million designated for the financing of the renovation program of the Magellan building, the covering of operating expenses, and the expenses associated with the servicing of the mortgage loan;
  3. the bank and financial debts of the group are the following:
    • a convertible bond loan of €28 million 2  held by the company Twenty Two Credit I, s.à r.l,
    • a non-bank subordinated loan of €78 million 2 from the company Twenty Two Credit I, s.à r.l,
    • a mortgage loan of €92 million 2 from the bank Helaba.  

1 : See press releases dated October 29th December,2018 and December 21st, 2018

2: principal and interests

The net sales proceeds of the sale of the Newtime building (€152.3 million) will be allocated to the reimbursement of the mortgage loan of Helaba (€92 million) and to the partial reimbursement of the non-bank subordinated loan (€60 million).

It is recalled that once the disposal of the Newtime building will be completed, the company REOF Holding S.à r.l, majority shareholder of Officiis Properties, will implement, pursuant to Article 236-6 of the Autorité des Marchés Financiers ("AMF") General Regulations, a public repurchase offer ( OPR ) for the entirety of the shares of Officiis Properties, and, if need be, for all securities granting access to the shareholders' equity or voting rights of the Company that it does not hold, under such conditions so as to enable the above-mentioned offer to be declared compliant by the AMF. REOF Holding S. à r.l. has not yet decided whether it will implement a compulsory buy out following the above-mentioned OPR .

The Company will soon designate an independent expert called upon to certify the fairness of the financial conditions of the above-mentioned offer.

Contact

Pierre Essig, Chief Executive Officer, Officiis Properties

52B, rue de la Bienfaisance, 75008 Paris

Tél. +33 1 83 92 33 86,

For more information, and/or to contact us, visit the company website: https:// officiis-properties.com : https://officiis-properties.com

About Officiis Properties (previously Züblin Immobilière France)

Officiis Properties is a listed property company that has opted for SIIC status and invests in office properties. Its real estate portfolio consists of two office buildings in the Paris region.

Officiis Properties' shares are listed on Euronext Paris' Compartment C, under the ISIN Code FR0010298901 and under the name of d'Officiis Propertie - Mnémonique OFP.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 271

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 139

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 190

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading

Top 5 Most Recently Viewed Articles

IONQ Achieves Record Stock Levels Amid Strong Growth Indicators

Updated Category News Views 243

IONQ Stock Reaches New Heights Recently, IONQ has made headlines as its stock skyrocketed to an unprecedented level of $47.41, marking a significant achievement for the company. With a robust market capitalization of $10.2 billion, this remarkable performance is a testament to the company's impressive growth trajectory and the strong belief investors hold in its future....

Continue Reading
Model 1 Commercial Vehicles Expands Leadership Team for Growth

Updated Category News Views 285

Model 1 Commercial Vehicles Announces Leadership Changes Model 1 Commercial Vehicles is thrilled to unveil a set of key leadership appointments aimed at enhancing its strategic direction and ensuring the company's ongoing success. These changes reflect the impressive growth trajectory the company has experienced over the past few years. Tony Matijevich Takes the Helm as...

Continue Reading
Texas Instruments: Unusual Options Trends Uncovered

Updated Category News Views 195

Texas Instruments Options Insights Financial powerhouses have made a notable bullish move on Texas Instruments. Our analysis reveals intriguing trends within the options market for Texas Instruments (NASDAQ: TXN), showcasing an unusual number of trades that pinpoint shifting market sentiments. Trading Sentiment Overview Diving deeper into the data, it appears that 58% of...

Continue Reading
SMCP Unveils Latest Interim Financial Report for 2025

Updated Category News Views 177

SMCP Announces Availability of Its Interim Financial Report SMCP is excited to share that its interim financial report for the six-month period ending June 30, 2025, is now available for public access. This report has been officially filed with the relevant regulatory authorities. Details on the Financial Report This financial report outlines the company's performance...

Continue Reading
Kevin O'Leary Discusses Business Leaders' Support for Trump

Updated Category News Views 159

Understanding O'Leary's Perspective on Business Leadership Kevin O’Leary, a prominent entrepreneur and investor from Shark Tank, has provided insight into the evolving relationship between business leaders and President Trump. In recent discussions, O’Leary emphasized that the admiration many tech CEOs and corporate leaders have for Trump is not solely about his tax...

Continue Reading